Free Access
Med Sci (Paris)
Volume 24, Number 12, Décembre 2008
Page(s) 1077 - 1082
Section M/S revues
Published online 15 December 2008
  1. Gonzalez de Aguilar JL, Echaniz-Laguna A, Fergani A, et al. Amyotrophic lateral sclerosis: all roads lead to Rome. J Neurochem 2007; 101 : 1153–60. [Google Scholar]
  2. Boillee S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006; 52 : 39–59. [Google Scholar]
  3. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362 : 59–62. [Google Scholar]
  4. Fischer LR, Culver DG, Tennant P, et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol 2004; 185 : 232–40. [Google Scholar]
  5. Frey D, Schneider C, Xu L, et al. Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. J Neurosci 2000; 20 : 2534–42. [Google Scholar]
  6. Pun S, Santos AF, Saxena S, et al. Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat Neurosci. 2006; 9 : 408–19. [Google Scholar]
  7. Guegan C, Przedborski S. Programmed cell death in amyotrophic lateral sclerosis. J Clin Invest 2003; 111 : 153–61. [Google Scholar]
  8. Rouaux C, Panteleeva I, Rene F, et al. Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J Neurosci 2007; 27 : 5535–45. [Google Scholar]
  9. Gould TW, Buss RR, Vinsant S, et al. Complete dissociation of motor neuron death from motor dysfunction by Bax deletion in a mouse model of ALS. J Neurosci 2006; 26 : 8774–86. [Google Scholar]
  10. Dewil M, De la Cruz VF, Van Den Bosch L, et al. Inhibition of p38 mitogen activated protein kinase activation and mutant SOD1 (G93A)-induced motor neuron death. Neurobiol Dis 2007; 26 : 332–41. [Google Scholar]
  11. Pramatarova A, Laganiere J, Roussel J, et al. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J Neurosci 2001; 21 : 3369–74. [Google Scholar]
  12. Lino MM, Schneider C, Caroni P. Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J Neurosci 2002; 22 : 4825–32. [Google Scholar]
  13. Boillee S, Yamanaka K, Lobsiger CS, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006; 312 : 1389–92. [Google Scholar]
  14. Clement AM, Nguyen MD, Roberts EA, et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003; 302 : 113–7. [Google Scholar]
  15. Pettmann B, Raoul C, Haase G. Mort des motoneurones dans la SLA : suicide ou meurtre ? Med Sci (Paris) 2006; 22 : 923–5. [Google Scholar]
  16. Boillée S, Lobsiger CS. Les cellules gliales : pas d’un si grand support pour les motoneurones. Med Sci (Paris) 2008; 24 : 124–6. [Google Scholar]
  17. Pehar M, Cassina P, Vargas MR, et al. Astrocytic production of nerve growth factor in motor neuron apoptosis: implications for amyotrophic lateral sclerosis. J Neurochem 2004; 89 : 464–73. [Google Scholar]
  18. Vargas MR, Pehar M, Cassina P, et al. Increased glutathione biosynthesis by Nrf2 activation in astrocytes prevents p75NTR-dependent motor neuron apoptosis. J Neurochem 2006; 97 : 687–96. [Google Scholar]
  19. Nagai M, Re DB, Nagata T, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 2007; 10 : 615–22. [Google Scholar]
  20. Di Giorgio FP, Carrasco MA, Siao MC, et al. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci 2007; 10 : 608–14. [Google Scholar]
  21. Yamanaka K, Chun SJ, Boillee S, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 2008; 11 : 251–3. [Google Scholar]
  22. Beers DR, Henkel JS, Xiao Q, et al. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2006; 103 : 16021–6. [Google Scholar]
  23. Dupuis L, Gonzalez de Aguilar JL, di Scala F, et al. Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis. Neurobiol Dis 2002; 10 : 358–65. [Google Scholar]
  24. Jokic N, Gonzalez de Aguilar JL, Pradat PF, et al. Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity. Ann Neurol 2005; 57 : 553–6. [Google Scholar]
  25. Pradat PF, Bruneteau G, Gonzalez de Aguilar JL, et al. Muscle Nogo-A expression is a prognostic marker in lower motor neuron syndromes. Ann Neurol 2007; 62 : 15–20. [Google Scholar]
  26. Jokic N, Gonzalez de Aguilar JL, Dimou L, et al. The neurite outgrowth inhibitor Nogo-A promotes denervation in an amyotrophic lateral sclerosis model. EMBO Rep 2006; 7 : 1162–7. [Google Scholar]
  27. Dobrowolny G, Giacinti C, Pelosi L, et al. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J Cell Biol 2005; 168 : 193–9. [Google Scholar]
  28. Miller TM, Kim SH, Yamanaka K, et al. Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2006; 103 : 19546–51. [Google Scholar]
  29. Towne C, Raoul C, Schneider BL, et al. Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice. Mol Ther 2008; 16 : 1018–25. [Google Scholar]
  30. Dupuis L, Oudart H, Rene F, et al. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci USA 2004; 101 : 11159–64. [Google Scholar]
  31. Fergani A, Oudart H, Gonzalez De Aguilar JL, et al. Increased peripheral lipid clearance in an animal model of amyotrophic lateral sclerosis. J Lipid Res 2007; 48 : 1571–80. [Google Scholar]
  32. Mattson MP, Cutler RG, Camandola S. Energy intake and amyotrophic lateral sclerosis. Neuromolecular Med 2007; 9 : 17–20. [Google Scholar]
  33. Maswood N, Young J, Tilmont E, et al. Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson’s disease. Proc Natl Acad Sci USA 2004; 101 : 18171–6. [Google Scholar]
  34. Rasouri S, Lagouge M, Auwerx J. SIRT1/PGC-1: un axe neuroprotecteur ? Med Sci (Paris) 2007; 23 : 840–4. [Google Scholar]
  35. Desport JC, Preux PM, Magy L, et al. Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am J Clin Nutr 2001; 74 : 328–34. [Google Scholar]
  36. Desport JC, Preux PM, Truong TC, et al. Nutritional status is a prognostic factor for survival in ALS patients. Neurology 1999; 53 : 1059–63. [Google Scholar]
  37. Desport JC, Torny F, Lacoste M, et al. Hypermetabolism in ALS: correlations with clinical and paraclinical parameters. Neurodegenerative Dis 2005; 2 : 202–7. [Google Scholar]
  38. Dupuis L, Corcia P, Fergani A, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 2008; 70 : 1004–9. [Google Scholar]
  39. Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis 2007; 26 : 1–13. [Google Scholar]
  40. Dupuis L, Di Scala F, Rene F, et al. Up-regulation of mitochondrial uncoupling protein 3 reveals an early muscular metabolic defect in amyotrophic lateral sclerosis. FASEB J 2003; 17 : 2091–93. [Google Scholar]
  41. Langui D, Lachapelle F, Duyckaerts C. Modèles animaux des maladies neuro-dégénératives. Med Sci (Paris) 2007; 23 : 180–6. [Google Scholar]
  42. Dobrowolny G, Aucello M, Rizzuto E, et al. Skeletal muscle is a primary target of SOD1G93A mediated toxicity. Cell Metab 2008; 8 : 425–36. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.